Core Viewpoint - Nuvation Bio Inc. is under investigation by the Schall Law Firm for potential violations of securities laws, particularly regarding misleading statements and undisclosed information that may have affected investors [1][2]. Financial Performance - Nuvation reported its Q4 and full year 2025 financial results on March 2, 2026, revealing that a significant portion of early patient starts for its IBTROZI oncology therapy were in later-line treatment settings [2]. - The company disclosed that 75% of treatment discontinuations were from these later-line patient populations, which contributed to a gap between the number of patients starting IBTROZI and its net product revenue growth [2]. - Following this announcement, shares of Nuvation fell by 25.3% the next day [2]. Legal Context - The Schall Law Firm is encouraging shareholders who suffered losses to participate in the investigation and discuss their rights [3]. - The firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [3].

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 most active penny stocks to buy. Bullish Analyst Sentiment on Nuvation Bio (NUVB) Amid Early Commercialization Progress Photo by National Cancer Institute on Unsplash As of March 16, 2026, Wall Street remains optimistic about Nuvation Bio Inc. (NYSE:NUVB). With over 90% of analysts covering Nuvation Bio Inc. (NYSE:NUVB) maintaining bullish ratings, the consensus price target is $12.00, indicating a potential upside of 166.67%. As investors focus on IBTRO ...

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Nuvation Bio Inc. (“Nuvation” or the “Company”) (NYSE: NUVB).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nuvation and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 2, 2 ...

Poster Presentations Overview:Title: Taletrectinib in tyrosine kinase inhibitor (TKI)-pretreated patients with ROS1+ non-small cell lung cancer (NSCLC): Updated data from TRUST-I and TRUST-IIPresenter: Geoffrey Liu, M.Sc., M.D., Professor, Princess Margaret Cancer Centre, Temerty School of Medicine, University of TorontoSession Title: Phase II Clinical TrialsDate: Tuesday, April 21, 2026Session Time: 2:00-5:00 p.m. PSTPoster Board Number: 9Abstract Number: #CT244 Nuvation Bio to Present Pivotal IBTROZI® (Ta ...

Nuvation Bio Inc. (NYSE:NUVB) is one of the best penny stocks to buy according to Reddit. On March 3, RBC Capital cut the price target on Nuvation Bio Inc. (NYSE:NUVB) to $13 from $12 while maintaining an Outperform rating on the shares. The rating update came after the company reported its fiscal Q4 results, with the firm telling investors in a research note that the launch of Ibtrozi is continually showing promise. Physicians are using increasing amounts of the drug in their ROS1 patients, driven by good ...

Summary of Nuvation Bio Conference Call Company Overview - **Company**: Nuvation Bio (NYSE:NUVB) - **Event**: 2026 Conference on March 11, 2026 Key Points on Ibtrozi Launch - **Launch Performance**: The Ibtrozi launch has been successful, treating 432 patients in the first two quarters, averaging over 200 patients per quarter, which is six times the initial performance of Augtyro [4][39] - **Sales Dynamics**: Sales have been successful across all territories with 47 sales representatives achieving success in various geographies [5] - **Lines of Therapy**: Majority of prescriptions are in later lines of therapy, typical for oncology launches, but there is a growing trend in first-line use [4][14] Patient Treatment Insights - **Duration of Therapy**: Progression-free survival in the first-line setting is approximately 46 months, decreasing significantly in later lines [9][11] - **Reimbursement Challenges**: Few reimbursement challenges have been reported, with only a small number of patients seeking assistance through the Nuvation Connect portal [12][14] - **Discontinuation Rates**: 75% of discontinuations are from third-line plus patients, indicating that earlier line patients are remaining on the drug longer [29] Financial Projections - **Sales Estimates**: The company is comfortable with a consensus estimate of just under $150 million for the first full year of sales, expecting growth to be non-linear [31][32] - **Gross to Net Dynamics**: The gross to net ratio was above 25% in the first quarter, with expectations for gradual improvement [38] Market Expansion Potential - **ROS1 Testing**: The market for ROS1 testing is expected to grow as RNA testing becomes standard, which is 30% more sensitive than DNA testing [41][42] - **NCCN Guidelines Impact**: Changes in NCCN guidelines are expected to increase ROS1 TKI use, as IO is now contraindicated [43][44] Competitive Landscape - **Comparison with Competitors**: Ibtrozi shows superior efficacy compared to Nuvalent's drug, with higher response rates and intracranial response rates [66][69] - **Adjuvant Plans**: Nuvation Bio is the only ROS1 TKI pursuing adjuvant studies, which could lead to significant market share [79][85] Safusidenib Development - **IDH1 Inhibitor**: Safusidenib shows promising results in low-risk, low-grade glioma, with a response rate of 44% compared to Vorasidenib's 11% [90] - **Future Studies**: Ongoing studies aim to expand approval across multiple glioma segments, with potential for approval based on response rates [91][96] Conclusion - Nuvation Bio is positioned strongly in the oncology market with Ibtrozi and Safusidenib, showing promising launch metrics, competitive advantages, and a clear path for future growth and market expansion.

Core Insights - The stock reaction following the conference call was considered unusual, with no new information presented beyond what was preannounced at JPMorgan [1] - The company highlighted robust new patient starts, which increased significantly, showing a 6x growth compared to the BMS launch, rising from 204 in Q3 to 216 in Q4 [1] Market Reaction - The market has experienced significant volatility this week, impacting stock performance [1] - The company aimed to provide additional context regarding the preannounced results during the conference call [1] Patient Metrics - New patient starts have been strong, indicating positive growth trends for the company [1] - The increase in new patient starts raises questions about the perceived gap between these starts and other performance metrics [1]

Core Insights - Nuvation Bio Inc. (NYSE:NUVB) is recognized as a promising low-cost stock under $5, particularly following the FDA approval and commercial launch of Ibtrozi (Taletrectinib) for ROS1-positive non-small cell lung cancer, with a significant uptake of 432 new patient starts by year-end, outpacing competitors by sixfold [1][2] Financial Performance - The company reported $41.9 million in revenue for Q4, supported by a robust cash position of $529.2 million, bolstered by international partnerships with Eisai and Nippon Kayaku [1] Drug Development and Market Strategy - Nuvation Bio is focusing on increasing revenue stability as first-line patient penetration improves through 2026, emphasizing Ibtrozi's differentiated clinical profile, including a 50-month median duration of response in TKI-naive patients and a favorable safety profile [2] - The company has initiated the TRUST-4 Phase 3 study targeting early-stage patients for Ibtrozi, and is advancing its second lead program, safusidenib, for IDH1-mutant glioma, with the Phase 3 SIGMA trial recently launched for high-grade patients [3][4]

Summary of Nuvation Bio Conference Call Company Overview - **Company**: Nuvation Bio - **Key Executives**: David Hung (Co-founder, President, and CEO), Philippe Sauvage (Chief Financial Officer) Core Industry Insights - **Industry**: Biotech, specifically oncology treatments - **Product Focus**: Taletrectinib (IBTROZI), a drug for ROS1-positive lung cancer Key Points and Arguments Market Reaction and Stock Performance - The stock reaction post-conference call was deemed unusual, with no new news released beyond what was pre-announced at JPMorgan [3][4] - New patient starts increased significantly, with a 6x growth compared to the BMS launch, from 204 in Q3 to 216 in Q4 [3][4] Patient Dynamics and Revenue Insights - A gap exists between new patient starts and revenue due to the nature of oncology launches, where the sickest patients are treated first [4][5] - Majority of patients treated in Q3 and Q4 were TKI-experienced, with a growing number of first-line patients expected [5][6] - Discontinuation rates were misinterpreted; 75% of discontinuations were in the third line or later, which is typical for oncology [7][10] - Duration of response (DOR) is significant, with first-line patients showing a DOR of 50 months, while second-line patients show around 12 months [8][9] Revenue Projections - Expected revenue for the year is $147 million, with a belief that the second half will outperform the first half [17][19] - Even without growth, maintaining 200 patients per quarter could yield around $220 million annually [18][19] Market Dynamics and Competition - Taletrectinib has a 90% response rate in first-line treatment, which is considered extraordinary in oncology [24][25] - The company believes it is becoming the standard of care among existing ROS1 TKIs, with a low discontinuation rate of 0.3% for the top six adverse events [39][40] Community vs. Academic Adoption - Initially, 70% of prescriptions came from academic centers, but there is a shift towards community centers, which is expected to increase testing rates [49][50] - The company is working to ensure that more patients are tested for ROS1 mutations to increase the adoption of Taletrectinib [54][56] International Expansion and Partnerships - A deal with Eisai was announced, with plans for European approval expected in Q2 of the following year [59][63] - The company anticipates lower pricing in Europe compared to the U.S. but sees it as a positive opportunity for market expansion [61][62] Future Development and Clinical Trials - The SIGMA phase 3 study for IDH1 mutant glioma is underway, targeting a significant unmet need in the market [67][68] - The company is also exploring a second study for grade 3 oligodendroglioma, with potential for early data readouts [75][76] Financial Health and Business Development - After receiving the next milestone payment from Eisai, the company expects to have about $620 million in cash, which is more than sufficient to reach profitability [100] Additional Important Insights - The company emphasizes the importance of access to their drug, which is relatively expensive, and is taking steps to ensure that patients can obtain it [38][39] - The oncology market is characterized by a high unmet need, particularly for late-line patients, which presents both challenges and opportunities for Nuvation Bio [44][45]

分组1 - Nuvation Bio Inc. reported a quarterly loss of $0.11 per share, which aligns with the Zacks Consensus Estimate, showing an improvement from a loss of $0.15 per share a year ago [1] - The company posted revenues of $41.87 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 52.63%, compared to revenues of $5.71 million in the same quarter last year [2] - Nuvation Bio has surpassed consensus revenue estimates four times over the last four quarters, although it has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed, losing about 34% since the beginning of the year, while the S&P 500 has gained 0.5% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $0.05 on revenues of $48.34 million, and for the current fiscal year, it is -$0.33 on revenues of $197.35 million [7] 分组3 - The Medical - Biomedical and Genetics industry, to which Nuvation Bio belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - The estimate revisions trend for Nuvation Bio was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]